Publications & Posters
Scholarly publications
Spinal Muscular Atrophy
Apitegromab
October 2022
WMS Hybrid Congress
Apitegromab in SMA: An analysis of multiple efficacy endpoints in the TOPAZ extension study (P.102)
Immuno-Oncology
SRK-181
September 2022
12th Annual World Clinical Biomarkers & CDx Summit
Development of a Comprehensive Biomarker Strategy for the Latent TGFβ1 Inhibitor SRK-181 Phase 1 Clinical Trial, DRAGON
Immuno-Oncology
SRK-181
September 2022
American College of Clinical Pharmacology Annual Meeting
Preliminary Population Pharmacokinetic Modeling of SRK-181 from Phase 1 Dose Escalation Study
Fibrosis
SRK-373
July 2022
Federation of American Societies for Experimental Biology
Selective Targeting of Matrix-Associated TGFβ1 is an Attractive Approach for Anti-Fibrotic Therapy
Spinal Muscular Atrophy
Apitegromab
June 2022
CURE SMA Annual Conference
Topaz Extension: 24-Month Efficacy and Safety: Apitegromab in Patients With Type 2 and Type 3 Spinal Muscular Atrophy (SMA)
Spinal Muscular Atrophy
Apitegromab
June 2022
CURE SMA Annual Conference
